ClinConnect ClinConnect Logo
Search / Trial NCT06586684

Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound

Launched by FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY · Sep 4, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Inclisiran Carotid Plaque Echocardiography Hyperlipidmia

ClinConnect Summary

This clinical trial is studying a medication called inclisiran to see how it affects carotid plaques, which are fatty deposits in the arteries that can increase the risk of heart problems. The goal is to understand if inclisiran can make these plaques more stable and less likely to cause serious cardiovascular events. This study will involve patients aged 18 to 75 years who have specific cholesterol levels and ultrasound-confirmed carotid plaques.

To be eligible, participants should not have any serious allergies to certain cholesterol medications, and they shouldn't have a history of major heart surgeries or strokes. This trial is currently not recruiting participants, but once it starts, those who join can expect to undergo ultrasound imaging to monitor the condition of their carotid plaques. This research aims to provide important information that could help doctors better manage patients with high cholesterol and carotid artery issues in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with carotid plaques as indicated by ultrasound
  • Men and women aged 18-75 years;
  • LDL-C \>3.4 mmol/L without regular statin therapy or LDL-C \>1.8 mmol/L after 4 weeks of statin lipid-lowering therapy.
  • Exclusion Criteria:
  • - Known allergies or contraindications to PCSK9 inhibitors and/or statin therapy;
  • Prior use of PCSK9 inhibitors;
  • Prior history of hemorrhagic stroke;
  • Prior coronary artery bypass grafting or coronary intervention;
  • Inability to perform OCT imaging or unclear imaging;
  • Severe renal insufficiency (creatinine clearance \< 30 mL/min);
  • Severe hepatic dysfunction;
  • Baseline triglycerides \> 5.6 mmol/L;
  • Pregnant or lactating women;
  • Life expectancy not exceeding 1 year;
  • In the judgment of the investigator, unsuitable for this study for any reason.

About First Affiliated Hospital Of Xinjiang Medical University

The First Affiliated Hospital of Xinjiang Medical University is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to conduct rigorous studies across various therapeutic areas. Committed to ethical standards and patient safety, the hospital collaborates with a network of experienced researchers and healthcare professionals to foster scientific advancements and contribute to the global medical community. Its mission is to enhance healthcare outcomes while ensuring the highest quality of clinical research.

Locations

Patients applied

0 patients applied

Trial Officials

Zhenyan Fu, PhD

Principal Investigator

First Affiliated Hospital of Xinjiang Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported